News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
686,889 Results
Type
Article (39427)
Company Profile (290)
Press Release (647172)
Section
Business (204417)
Career Advice (1990)
Deals (35431)
Drug Delivery (87)
Drug Development (81045)
Employer Resources (168)
FDA (16102)
Job Trends (14862)
News (345383)
Policy (32470)
Tag
Academia (2557)
Alliances (49235)
Alzheimer's disease (1228)
Approvals (16030)
Artificial intelligence (127)
Bankruptcy (352)
Best Places to Work (11582)
Biotechnology (207)
Breast cancer (116)
Cancer (1033)
Cardiovascular disease (86)
Career advice (1660)
Cell therapy (220)
Clinical research (64286)
Collaboration (366)
Compensation (188)
COVID-19 (2545)
C-suite (89)
Data (1044)
Diabetes (151)
Diagnostics (6145)
Earnings (84905)
Employer resources (146)
Events (109708)
Executive appointments (279)
FDA (16609)
Funding (332)
Gene therapy (171)
GLP-1 (573)
Government (4330)
Healthcare (18745)
Infectious disease (2627)
Inflammatory bowel disease (108)
Interviews (308)
IPO (16311)
Job creations (3634)
Job search strategy (1418)
Layoffs (413)
Legal (7853)
Lung cancer (165)
Manufacturing (172)
Medical device (13173)
Medtech (13178)
Mergers & acquisitions (19178)
Metabolic disorders (392)
Neuroscience (1486)
NextGen Class of 2024 (6517)
Non-profit (4475)
Northern California (1420)
Obesity (227)
Opinion (178)
Patents (98)
People (56431)
Phase I (19975)
Phase II (28320)
Phase III (21105)
Pipeline (441)
Postmarket research (2557)
Preclinical (8525)
Radiopharmaceuticals (234)
Rare diseases (207)
Real estate (5911)
Regulatory (21523)
Research institute (2323)
Resumes & cover letters (349)
Southern California (1263)
Startups (3582)
United States (13053)
Vaccines (555)
Weight loss (166)
Date
Last 7 days (920)
Last 30 days (3440)
Last 365 days (35525)
2024 (32218)
2023 (40212)
2022 (51334)
2021 (55872)
2020 (54244)
2019 (46652)
2018 (35128)
2017 (32209)
2016 (31570)
2015 (37635)
2014 (31385)
2013 (26428)
2012 (28651)
2011 (29330)
2010 (27397)
Location
Africa (714)
Arizona (191)
Asia (37279)
Australia (6101)
California (3196)
Canada (1254)
China (238)
Colorado (142)
Connecticut (143)
Europe (80033)
Florida (438)
Georgia (112)
Illinois (338)
Indiana (190)
Kansas (96)
Maryland (570)
Massachusetts (2533)
Michigan (153)
Minnesota (269)
New Jersey (922)
New York (927)
North Carolina (691)
Northern California (1420)
Ohio (133)
Pennsylvania (816)
South America (1093)
Southern California (1263)
Texas (435)
Utah (88)
Washington State (351)
686,889 Results for "triumvira immunologics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Triumvira Immunologics Announces Publication Demonstrating the Safety and Efficacy of TAC T Cells Targeting Claudin 18.2 in Solid Tumors
October 15, 2024
·
4 min read
Press Releases
Triumvira Immunologics to Present New Clinical Data from Ongoing Claudin 18.2 Phase 1 Study in Late-Breaking Oral Presentation at 39th SITC Annual Meeting
October 30, 2024
·
3 min read
Press Releases
Triumvira Immunologics’ Late-Breaking Abstract Selected for Oral Presentation at the 39th SITC Annual Meeting Demonstrates Preliminary Safety and Promising Clinical Activity of TAC01-CLDN18.2 Cell Therapy in Patients with Solid Tumors
November 12, 2024
·
4 min read
Deals
Alternative funding strategies to discuss at JPM with Halia Therapeutics, the ADDF and Triumvira Immunologics
BioSpace and guests from Halia Therapeutics, Triumvira Immunologics and the Alzheimer’s Drug Discovery Foundation discuss alternative financing strategies to consider for 2024. Listen now.
January 4, 2024
·
1 min read
·
BioSpace Insights
Triumvira Immunologics to Present Clinical Data at the 2024 ASCO Gastrointestinal Cancers Symposium
Triumvira Immunologics today announced that it will present two abstracts at the 2024 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium in San Francisco, California, from January 18-20, 2024.
December 19, 2023
·
3 min read
Drug Development
Triumvira Immunologics Announces First Patient Dosed in Phase I/II Cell Therapy Trial of TAC101-CLDN18.2 for the Treatment of Claudin 18.2+ Solid Tumors
Triumvira Immunologics today announced that the first patient has been dosed in its TACTIC-3 trial, a Phase I/II study, (NCT05862324) investigating the safety and efficacy of autologous TAC-T cell asset, TAC101-CLDN18.2, targeting Claudin 18.2+ solid tumors.
February 5, 2024
·
3 min read
Triumvira Immunologics to Present New Clinical and Preclinical Data on its TAC-T Cell Technology at SITC 2023 Annual Meeting
Triumvira Immunologics today announced that it will participate with one oral presentation and four posters at the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting in San Diego, California, from November 1-5.
October 30, 2023
·
4 min read
Business
FDA’s CAR T Probe ‘Not a Big Deal’ for Oncology-Focused Biotechs: Triumvira President
Triumvira Immunologics’ president and chief operating officer Rob Williamson noted that cell therapy companies might still have an uphill battle unless they can differentiate.
January 10, 2024
·
2 min read
·
Tyler Patchen
Business
Triumvira Immunologics Strengthens its Leadership Team with Three Accomplished Life Sciences Executives
Triumvira Immunologics today announced the strengthening of its leadership team with the appointments of Mr. Robert Williamson as President, Chief Operating Officer and member of the Board of Directors, Mr. Jeffrey Erickson as VP of Business Development, and Mr. Chris Murray as VP of Human Resources.
July 20, 2023
·
4 min read
Drug Development
Triumvira Immunologics Announces First Patient Dosed in Phase II of TACTIC-2 Cell Therapy Trial for the Treatment of HER2+ Gastric and GEJ Cancers
Triumvira Immunologics announced that the first patient has been dosed in Phase II of its Phase I/II study TACTIC-2 investigating the safety and efficacy of autologous TAC-T cell lead asset, TAC01-HER2, in targeting HER2 in relapsed or refractory gastric and gastroesophageal junction tumors.
October 26, 2023
·
2 min read
1 of 68,689
Next
